Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...

Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost ...

Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

In a significant move reflecting confidence in the biopharmaceutical sector, Mitsubishi UFJ Asset Management Co. Ltd. has enhanced its investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand ...

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...